DK1414828T3 - Antitumoranaloger - Google Patents

Antitumoranaloger

Info

Publication number
DK1414828T3
DK1414828T3 DK02753134T DK02753134T DK1414828T3 DK 1414828 T3 DK1414828 T3 DK 1414828T3 DK 02753134 T DK02753134 T DK 02753134T DK 02753134 T DK02753134 T DK 02753134T DK 1414828 T3 DK1414828 T3 DK 1414828T3
Authority
DK
Denmark
Prior art keywords
antitumor
analogues
ecteinascidin
derivatives
antitumor analogues
Prior art date
Application number
DK02753134T
Other languages
Danish (da)
English (en)
Inventor
Valentin Martinez
Pilar Gallego
Carmen Cuevas
Simon Munt
Ignacio Manzanares
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Application granted granted Critical
Publication of DK1414828T3 publication Critical patent/DK1414828T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
DK02753134T 2001-08-07 2002-08-06 Antitumoranaloger DK1414828T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0119243.4A GB0119243D0 (en) 2001-08-07 2001-08-07 Antitumoral analogs of ET-743
PCT/GB2002/003592 WO2003014127A1 (en) 2001-08-07 2002-08-06 Antitumoral analogs

Publications (1)

Publication Number Publication Date
DK1414828T3 true DK1414828T3 (da) 2008-02-04

Family

ID=9919954

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02753134T DK1414828T3 (da) 2001-08-07 2002-08-06 Antitumoranaloger

Country Status (23)

Country Link
US (1) US7763615B2 (ja)
EP (3) EP1414828B9 (ja)
JP (2) JP4684552B2 (ja)
KR (1) KR20040032150A (ja)
CN (1) CN100334094C (ja)
AT (1) ATE374777T1 (ja)
AU (1) AU2002313540B2 (ja)
CA (1) CA2455768C (ja)
CY (1) CY1107830T1 (ja)
DE (1) DE60222775T2 (ja)
DK (1) DK1414828T3 (ja)
ES (1) ES2294151T3 (ja)
GB (1) GB0119243D0 (ja)
HK (1) HK1065786A1 (ja)
HU (1) HU229779B1 (ja)
IL (2) IL160051A0 (ja)
MX (1) MXPA04001240A (ja)
NO (1) NO337476B1 (ja)
NZ (1) NZ530837A (ja)
PL (1) PL218295B1 (ja)
PT (1) PT1414828E (ja)
RU (1) RU2283842C2 (ja)
WO (1) WO2003014127A1 (ja)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US8716308B2 (en) * 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
US9073925B2 (en) * 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8618299B2 (en) * 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
WO2011003005A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
US8629158B2 (en) * 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
CN103038240A (zh) * 2010-05-25 2013-04-10 法马马有限公司 制备海鞘素化合物的合成方法
ES2790414T3 (es) * 2010-11-12 2020-10-27 Pharma Mar Sa Terapia de combinación con un inhibidor de topoisomerasa
MX2013005652A (es) 2010-11-26 2013-09-13 Nec Corp Dispositivo de codificacion de video, dispositivo de decodificacion de video, metodo de codificacion de video, metodo de decodificacion de video, y programa.
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
WO2017067670A1 (en) 2015-10-23 2017-04-27 Pharmathen S.A. A novel process for the preparation of tryptamines and derivatives thereof
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
CA3148690A1 (en) 2019-09-03 2021-03-11 Ioannis METAXAS Lurbinectedin in the treatment of malignant mesothelioma
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
US20230027502A1 (en) * 2019-11-21 2023-01-26 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
WO2021228414A1 (en) 2020-05-14 2021-11-18 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
MA56827B2 (fr) * 2019-11-21 2023-09-27 Pharma Mar Sa Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
AR121894A1 (es) 2020-04-21 2022-07-20 Pharma Mar Sa Conjugados de anticuerpos de fármacos
WO2021218896A1 (zh) * 2020-04-26 2021-11-04 江苏恒瑞医药股份有限公司 海鞘素类衍生物及其制备方法与医药用途
CA3191207A1 (en) 2020-09-04 2022-03-10 Guido Kroemer Combination of lurbinectedin and immune checkpoint inhibitor
WO2022101255A1 (en) 2020-11-10 2022-05-19 Pharma Mar, S.A. Lurbinectedin and irinotecan combinations
WO2023031960A1 (en) * 2021-08-31 2023-03-09 Natco Pharma Limited Novel crystalline polymorph of lurbinectedin and improved process for the preparation of lurbinectedin
AU2022381992A1 (en) 2021-11-08 2024-05-16 Pharma Mar, S.A. Lurbinectedin and atezolizumab combinations
CN115246846A (zh) * 2021-11-19 2022-10-28 江苏慧聚药业股份有限公司 卢比替定新晶型及其制备
CN115304619A (zh) * 2022-04-08 2022-11-08 上海皓元医药股份有限公司 一种卢比替定的晶型及其制备方法
CN114940682A (zh) * 2022-05-18 2022-08-26 博瑞制药(苏州)有限公司 芦比替定的晶型及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
JP2562162B2 (ja) 1986-06-09 1996-12-11 ユニバーシティ・オブ・イリノイ エクテインアシジン729、743、745、759a、759bおよび770
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
BR9909488B1 (pt) 1998-04-06 2011-02-08 ecteinascidinas semi-sintéticas e composição farmacêutica.
AU759281B2 (en) * 1998-05-11 2003-04-10 Pharma Mar S.A. Metabolites of ecteinascidin 743
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
CA2397597A1 (en) * 2000-01-19 2001-07-26 The Trustees Of Columbia University In The City Of New York Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
SI1280809T1 (sl) * 2000-04-12 2005-12-31 Pharma Mar Sa Antitumorski ekteinascidin derivati
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.

Also Published As

Publication number Publication date
NO20040961L (no) 2004-03-05
KR20040032150A (ko) 2004-04-14
US20060128711A1 (en) 2006-06-15
RU2283842C2 (ru) 2006-09-20
PL218295B1 (pl) 2014-11-28
AU2002313540B2 (en) 2008-05-22
EP2270018A1 (en) 2011-01-05
EP1414828B1 (en) 2007-10-03
HK1065786A1 (en) 2005-03-04
RU2004106617A (ru) 2005-04-10
HUP0401174A2 (hu) 2005-09-28
IL160051A0 (en) 2004-06-20
EP1806349A1 (en) 2007-07-11
ATE374777T1 (de) 2007-10-15
JP2005501093A (ja) 2005-01-13
PL367940A1 (en) 2005-03-07
DE60222775T2 (de) 2008-07-17
NO337476B1 (no) 2016-04-18
CA2455768C (en) 2011-10-11
CA2455768A1 (en) 2003-02-20
ES2294151T3 (es) 2008-04-01
IL160051A (en) 2012-01-31
PT1414828E (pt) 2007-12-27
MXPA04001240A (es) 2004-06-03
CN100334094C (zh) 2007-08-29
JP4684552B2 (ja) 2011-05-18
CN1564822A (zh) 2005-01-12
JP2011026331A (ja) 2011-02-10
HUP0401174A3 (en) 2005-12-28
HU229779B1 (en) 2014-07-28
CY1107830T1 (el) 2013-06-19
EP1414828A1 (en) 2004-05-06
GB0119243D0 (en) 2001-10-03
WO2003014127A1 (en) 2003-02-20
EP1414828B9 (en) 2008-02-20
DE60222775D1 (de) 2007-11-15
NZ530837A (en) 2005-07-29
US7763615B2 (en) 2010-07-27

Similar Documents

Publication Publication Date Title
DK1414828T3 (da) Antitumoranaloger
SV2003001076A (es) Compuestos y procedimientos antitumorales ref. x-14776
NO20042279L (no) Kinazolinderivater som antitumormidler
NO20042288L (no) Kinazolinderivater som antitumormidler
CY1108707T1 (el) Αναλογα νοσισεπτινης
DE60229736D1 (de) Spiroinden- und spiroindan-verbindungen
NO20014759L (no) C(7)-estersubstituerte taxaner som antitumormidler
ES2184149T3 (es) Paclitaxeles 6-tio sustituidos.
ES2176212T3 (es) Eteres de fosfonooximetilicos o metiltiometilicos de derivados de taxano como agentes antitumorales.
CY1108454T1 (el) Ενωσεις σπειροπυραζολιου
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
CY1108456T1 (el) Ενωσεις βενζιμιδαζολονης
NO20015477D0 (no) 4,5,6,7-tetrahydroindazol-derivater som anti-tumor midler
SV2003000981A (es) Fenil-heterociclil-eteres ref. pcs10973
ATE315380T1 (de) Epothilon zusammensetzungen
NO20014753L (no) C(10)-karbonatsubstituerte taxaner som antitumormidler
MA27240A1 (fr) Derives d'imidazoquinoleine
NO20014755L (no) C(7)-karbonatsubstituerte taxaner som antitumormidler
BR0104352A (pt) Taxanos substituìdos por c10 carbamoilóxi como agentes antitumorais
DK1165549T3 (da) C7 carbamoyloxy-substituerede taxaner som antitumormidler
ATE250340T1 (de) 7-methylthiooxomethyl- und 7- methylthiodioxomethyl-paclitaxele
ATE282611T1 (de) Stolonoxide
ATE478155T1 (de) Glycopeptidantibiotika
ECSP993288A (es) ACTIVADORES DE hPPARy y hPPARa
DK1177185T3 (da) 4,5,6,7-tetrahydroindazolderivater som antitumormidler